ÃÑ 463ÆäÀÌÁö

321ÆäÀÌÁö º»¹®½ÃÀÛ

312
õ¿¬¹°ÁúÀ» ÀÌ¿ëÇÑ µ¿¹°Áúº´ÀÇ ¿¹¹æ ¹× Ä¡·á
8. Spectroscopic characterization of antibodies adsorbed to aluminium adjuvants:
correlation with antibody vaccine immunogenicity. Vaccine 23 (2005) 1686-1694.
9. Enhancement of the immune response to hepatitis B virus vaccine by antigen
specific IgM. Immunology Letters 73 (2000) 1-6.
10. Immunotherapeutic perspective for bispecific antibodies. Immunology Today
21(8) 391-397.
11. Influence of bispecific antibodies on the in vitro bactericidal activity of bovine
neutrophils against
Staphylococcus aureus. J Dairy Sci 2000 83 2269-2275.
12. Different levels of natural antibodies in chickens divergently selected for speci-
fic antibody responses. Developmental and Comparative Immunology 28 (2004)
39-49.
13. Adoptive transfer of natural antibodies to non-immunized chicken affects subse-
quent antigen-specific humoral and cellular immune responses. Developmental
and Comparative Immunology 28 (2004) 51-60.
14. CD40 antibody as a potent immunological adjuvant: CD40 antibody provides the
CD40 signal to B cells, but does not substitute for T cell help in responses to
TD antigens. Vaccine 23 (2005) 3477-3482.
15. Natural antibodies and complement link innate and acquired immunity. Immuno-
logy Today 2000 21(12) 624-627.
16. Polytufsin: its possible effects and mechanism during macrophage activation.
Immunology Letters, 46 (1995) 177-182.
´Ù. º¸Ã¼(Complement)
»ý¸íü´Â »ýÁ¸Àü·«À¸·Î ħÀԹ̻ý¹°¿¡ ´ëÇÑ °­ÇÑ ¹æ¾î±âÀüÀ» °®°í ÀÖÀ¸¸ç, ±× ¹æ¾î±âÀüÀÇ
Çϳª°¡ 30Á¾ ÀÌ»óÀÇ Ç÷û°ú ¼¼Æ÷Ç¥¸é ¼ººÐÀ¸·Î ±¸¼ºµÇ¾î ÀÖ´Â º¸Ã¼°èÀÌ´Ù. º¸Ã¼°è´Â õ¿¬
¹× ȹµæ¸é¿ª°èÀÇ ÀϺημ­ º´¿øüÀÇ Àνİú Á¦°Å¿¡ °øÁ¶ÇÑ´Ù. ¶ÇÇÑ º¸Ã¼°è´Â ¹«Ã´Ãßµ¿¹°¿¡¼­
°¡Àå °íµµ·Î Á¶Á÷µÈ õ¿¬¸é¿ª°èÀÇ Çϳª·Î, ÀÌ ¸é¿ª°è´Â 6-7¾ï³â µ¿¾È ±×°ÍÀÇ Çٽɱ¸¼ººÐ°ú
ÇÔ²² ¹« ôÃßµ¿¹° ³»¿¡ Á¸ÀçÇÏ¿© ¿Ô´Ù. º¸Ã¼°è´Â Ç×ü¹ÝÀÀÀ» °£Á¢ÀûÀ¸·Î Áõ°­½ÃÅ°°í ¿ëÇØÈ°¼º,
¿°Áõ ±×¸®°í ¿É¼Ò´ÑÀÛ¿ë¿¡ ÀÇÇØ Á÷Á¢ÀûÀ¸·Î °¨¿°¿¡ ´ëÇÑ ¼÷ÁÖ¹æ¾î¿¡ ±â¿©ÇÑ´Ù. º¸Ã¼È°¼ºÈ­
¿¡´Â 3°¡Áö °æ·Î(pathway) Áï, ÀüÇüÀû °æ·Î(classical pathway), ´ëü°æ·Î(alterna-tive
pathway) ±×¸®°í ·ºÆ¾°æ·Î(lectin pathway)°¡ ÀÖ´Ù. ºñ·Ï ÀÌµé °æ·Î±âÀüÀº ´Ù¸¥ ÀνıâÀü¿¡
ÀÇÇÏ¿© À¯¹ßµÇÁö¸¸, ÀÌ ¼¼ °¡Áö ±âÀü ¸ðµÎ°¡ º¸Ã¼ C3b¿¡ ÀÇÇÑ ¹Ì»ý¹°ÀÇ ¿É¼Ò´ÑÈ­¸¦ À̲ø¸ç
C3a¿Í C5a°°Àº ¿°Áõ¼º ÆéƼµå¿Í ¿ëÇØ ¹× ÇÁ·Î¿°Áõ¼º ¼¼Æ÷¸·°ø°Ýº¹ÇÕü((pro-inflammatory
membrane attack complex, MAC, C5b-9)¸¦ ¹ß»ý½ÃŲ´Ù. º¸Ã¼ÀÇ ÀüÇüÀû°æ·Î´Â Ç׿ø¿¡ °áÇÕÇÑ
IgG, IgM Ç×ü¿¡ ÀÇÇϰųª, ÁöÁú´Ù´ç·ù(LPS)ÀÇ ¸®Çǵå A(lipid A)¿¡ ÀÇÇϰųª, ¶Ç´Â ¹Ì»ý¹°
´Ù´ç·ù¸¦ ÀνÄÇÏ´Â C-¹ÝÀÀ¼º´Ü¹é(C-reactive protein)¿¡ ÀÇÇؼ­ È°¼ºÈ­µÈ´Ù. ·ºÆ¾°æ·Î
(lectin pathway)´Â »ì¸ð³Ú¶ó±ÕÀ̳ª ³×À̼¼¸®¾Æ±Õ(Neisseria)°°Àº ¹Ì»ý¹° ÁöÁú´Ù´ç·ù¿¡
ÀÖ´Â ¸¸³­(mannan)¿¡ ¸¸³ë½º°áÇÕ ·ºÆ¾ÀÇ °áÇÕ¿¡ ÀÇÇØ È°¼ºÈ­µÈ´Ù. ´ëü°æ·Î´Â C3b¿¡ ´ëÇÑ
°áÇÕÀÚ¸®¿¡ ±×¶÷ À½, ¾ç¼º±ÕÀ¯·¡ ´Ù´ç·ù³ª ´ç´Ü¹é(glycoprotein)ÀÌ °áÇÕÇÒ ¶§ È°¼ºÈ­µÈ´Ù.
¿©ÇÏÆ° IgG, C-¹ÝÀÀ¼º´Ü¹é, ¸¸³ë½º°áÇÕ ·ºÆ¾ ¸ðµÎ°¡ Ž½Ä¼¼Æ÷¿¡ ÀÖ´Â ¼ö¿ëü¿¡ °áÇÕÇÔÀ¸·Î
½á Á÷Á¢ÀûÀÎ ¿É¼Ò´ÑÈ­¸¦ ÀÌ·ç¸ç ¼¼Æ÷µéÀ» ¿ëÇØÇÑ´Ù. ±×¶÷ ¾ç¼º±ÕÀÇ ¼¼Æ÷º®Àº º¸Ã¼¿¡ ÀÇÇÑ

321ÆäÀÌÁö º»¹®³¡



ÇöÀç Æ÷Ä¿½ºÀÇ ¾Æ·¡³»¿ëµéÀº µ¿ÀÏÇÑ ÄÁÅÙÃ÷¸¦ °¡Áö°í ÆäÀÌÁö³Ñ±è È¿°ú¹× ½Ã°¢Àû È¿°ú¸¦ Á¦°øÇÏ´Â ÆäÀÌÁöÀ̹ǷΠ½ºÅ©¸°¸®´õ »ç¿ëÀÚ´Â ¿©±â±îÁö¸¸ ³¶µ¶ÇϽðí À§ÀÇ ÆäÀÌÁöÀ̵¿ ¸µÅ©¸¦ »ç¿ëÇÏ¿© ´ÙÀ½ÆäÀÌÁö·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
»ó´Ü¸Þ´º ¹Ù·Î°¡±â ´ÜÃàÅ°¾È³» : ÀÌÀüÆäÀÌÁö´Â ÁÂÃø¹æÇâÅ°, ´ÙÀ½ÆäÀÌÁö´Â ¿ìÃø¹æÇâÅ°, ùÆäÀÌÁö´Â »ó´Ü¹æÇâÅ°, ¸¶Áö¸·ÆäÀÌÁö´Â ÇϴܹæÇâÅ°, ÁÂÃøÈ®´ëÃà¼Ò´Â insertÅ°, ¿ìÃøÈ®´ëÃà¼Ò´Â deleteÅ°